Clinical trial

CAMEO: Canadian Methotrexate and Etanercept Outcome Study

NCT00654368

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-06-01

PhasePHASE4

Study timeline

Study start (unknown)2008-06-01Date precision: month

Registry last updated2014-07-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritisunresolved

Interventions

EtanerceptBIOLOGICAL

MethotrexateDRUG · verified · RxNorm: methotrexate

Sponsors & collaborators

Amgenlead sponsor

Wyeth is now a wholly owned subsidiary of Pfizercollaborator

Mapped research locations

MontrealQuebec, Canada3 TorontoOntario, Canada2 VancouverBritish Columbia, Canada1 OttawaOntario, Canada1 LondonOntario, Canada1 HamiltonOntario, Canada1 QuébecQuebec, Canada1 WinnipegManitoba, Canada1 SaskatoonSaskatchewan, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00654368 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.